Chinese drug makers are tweaking the tumor-killing payloads of their antibody-drug conjugate (ADC) candidates, as the key component of these emerging oncologic agents comes to the fore in the global race for potential best-in-class therapies.
While a number of cytotoxic candidates are up for grabs, ADC developers in China are primarily focused on the DNA topoisomerase I inhibitors (TOP1i) class, already well represented by the...